La Jolla Pharmaceutical (NASDAQ:LJPC) Director Laura L. Douglass sold 10,000 shares of the business’s stock in a transaction on Saturday, December 29th. The stock was sold at an average price of $32.32, for a total value of $323,200.00. Following the sale, the director now directly owns 6,000 shares in the company, valued at $193,920. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

La Jolla Pharmaceutical (NASDAQ LJPC) traded up $0.68 during trading hours on Wednesday, reaching $33.85. The company had a trading volume of 409,334 shares, compared to its average volume of 594,634. The firm has a market capitalization of $749.62, a price-to-earnings ratio of -6.64 and a beta of 1.63. La Jolla Pharmaceutical has a 52-week low of $16.71 and a 52-week high of $39.28.

La Jolla Pharmaceutical (NASDAQ:LJPC) last issued its earnings results on Thursday, October 26th. The biopharmaceutical company reported ($1.19) earnings per share for the quarter, topping the consensus estimate of ($1.24) by $0.05. sell-side analysts predict that La Jolla Pharmaceutical will post -4.91 EPS for the current year.

A number of hedge funds have recently modified their holdings of the business. FMR LLC increased its position in La Jolla Pharmaceutical by 0.6% in the 2nd quarter. FMR LLC now owns 3,313,318 shares of the biopharmaceutical company’s stock worth $98,637,000 after purchasing an additional 18,883 shares during the last quarter. State Street Corp increased its position in La Jolla Pharmaceutical by 235.1% in the 2nd quarter. State Street Corp now owns 1,180,368 shares of the biopharmaceutical company’s stock worth $35,140,000 after purchasing an additional 828,081 shares during the last quarter. Janus Henderson Group PLC acquired a new position in La Jolla Pharmaceutical in the 2nd quarter worth about $25,191,000. Vanguard Group Inc. increased its position in La Jolla Pharmaceutical by 23.3% in the 2nd quarter. Vanguard Group Inc. now owns 816,779 shares of the biopharmaceutical company’s stock worth $24,316,000 after purchasing an additional 154,494 shares during the last quarter. Finally, Redmile Group LLC increased its position in La Jolla Pharmaceutical by 18.0% in the 2nd quarter. Redmile Group LLC now owns 713,280 shares of the biopharmaceutical company’s stock worth $21,234,000 after purchasing an additional 108,810 shares during the last quarter.

Several research analysts recently weighed in on the company. Cowen reissued a “buy” rating and set a $55.00 price target on shares of La Jolla Pharmaceutical in a research report on Friday, October 27th. ValuEngine raised La Jolla Pharmaceutical from a “strong sell” rating to a “sell” rating in a research report on Tuesday, December 26th. SunTrust Banks set a $65.00 price target on La Jolla Pharmaceutical and gave the company a “buy” rating in a research report on Thursday, December 28th. Zacks Investment Research raised La Jolla Pharmaceutical from a “hold” rating to a “buy” rating and set a $39.00 price target on the stock in a research report on Wednesday, November 1st. Finally, Jefferies Group reissued a “buy” rating and set a $40.00 price target on shares of La Jolla Pharmaceutical in a research report on Tuesday, October 3rd. Two research analysts have rated the stock with a sell rating, one has assigned a hold rating and seven have issued a buy rating to the stock. The company has an average rating of “Buy” and an average price target of $57.14.

ILLEGAL ACTIVITY NOTICE: This report was posted by American Banking News and is the sole property of of American Banking News. If you are accessing this report on another site, it was illegally stolen and republished in violation of United States and international trademark and copyright laws. The legal version of this report can be viewed at https://www.americanbankingnews.com/2018/01/03/laura-l-douglass-sells-10000-shares-of-la-jolla-pharmaceutical-ljpc-stock.html.

La Jolla Pharmaceutical Company Profile

La Jolla Pharmaceutical Company is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapies to improve outcomes in patients suffering from life-threatening diseases. LJPC-501 is its formulation of angiotensin II for the potential treatment of catecholamine-resistant hypotension (CRH).

Insider Buying and Selling by Quarter for La Jolla Pharmaceutical (NASDAQ:LJPC)

Receive News & Ratings for La Jolla Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for La Jolla Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.